Alatrofloxacin

Summary

Alatrofloxacin (CHEMBL1201197) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 558.5 Da · C26H25F3N6O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201197
Name	Alatrofloxacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3086677
Molecular formula	C26H25F3N6O5
Molecular weight	558.5
InChIKey	UUZPPAMZDFLUHD-LZGARRQBSA-N

SMILES: C[C@@H](C(=O)N[C@@H](C)C(=O)NC1[C@H]2[C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F)N

IUPAC name: 7-[(1R,5S)-6-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]propanoyl]amino]-3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid

Also known as: Alatrofloxacin, Alatrofloxacine, Alatrofloxacino, alatrofloxacin, ALATROFLOXACIN

Parent form; salt/anhydrous children: CHEMBL1200498

Patent coverage: 20 distinct patent families (24 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).